Cx 2 Mab-5: A Novel Anti-Mouse CXCR2 Monoclonal Antibody Developed by N-Terminus Peptide Immunization for Multiple Applications

Abstract

The CXC chemokine receptor 2 (CXCR2) is a member of the G-protein-coupled receptor superfamily and regulates a diverse range of immune responses and tumor progression. CXCR2 is expressed on immune cells, especially neutrophils, and is involved in various immune responses by interacting with its chemokine ligands. Therefore, the development of sensitive monoclonal antibodies (mAbs) for CXCR2 has been desired for treatment and diagnosis. This study established a novel sensitive anti-mouse CXCR2 (mCXCR2) mAb; Cx₂Mab-5 (rat IgG_2a, κ), using the mCXCR2 synthetic N-terminus peptide immunization method. In flow cytometry, Cx₂Mab-5 recognized mCXCR2-overexpressed Chinese hamster ovary-K1 cells (CHO/mCXCR2) and WEHI-3B (murine myelomonocytic leukemia cell) cells, which express endogenous mCXCR2. Cx₂Mab-5 did not cross-react with other mouse CC, CXC, CX3C, and XC chemokine receptors. Cx₂Mab-5 showed a moderate binding affinity for both CHO/mCXCR2 and WEHI-3B. Furthermore, Cx₂Mab-5 detected mCXCR2 in Western blot and immunohistochemistry in CHO/mCXCR2 cells, but a commercially available anti-mCXCR2 mAb (clone SA045E1) did not. Hence, Cx₂Mab-5 can be a valuable tool for analyzing mCXCR2-positive cells in mouse tissues.

Keywords

chemokine receptor CXCR2 monoclonal antibody flow cytometry

Get full access to this article

View all access options for this article.

References

López-Cotarelo

, Gómez-Moreira

, Criado-García

, et al. Beyond chemoattraction: Multifunctionality of chemokine receptors in leukocytes. Trends Immunol, 2017; 38(12):927–941; doi: 10.1016/j.it.2017.08.004

Nagarsheth

, Wicha

, Zou

. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol, 2017; 17(9):559–572; doi: 10.1038/nri.2017.49

Rajagopalan

, Rajarathnam

. Structural basis of chemokine receptor function–A model for binding affinity and ligand selectivity. Biosci Rep, 2006; 26(5):325–339; doi: 10.1007/s10540-006-9025-9

Kaplan

. Chemokines, chemokine receptors and allergy. Int Arch Allergy Immunol, 2001; 124(4):423–431; doi: 10.1159/000053777

Shachar

, Karin

. The dual roles of inflammatory cytokines and chemokines in the regulation of autoimmune diseases and their clinical implications. J Leukoc Biol, 2013; 93(1):51–61; doi: 10.1189/jlb.0612293

O’Hayre

, Salanga

, Handel

, et al. Chemokines and cancer: Migration, intracellular signalling and intercellular communication in the microenvironment. Biochem J, 2008; 409(3):635–649; doi: 10.1042/bj20071493

Saha

, Sano

, Sharma

, et al. Molecular basis of promiscuous chemokine binding and structural mimicry at the C-X-C chemokine receptor, CXCR2. Mol Cell, 2025; 85(5):976–988.e979; doi: 10.1016/j.molcel.2025.01.024

Lazennec

, Rajarathnam

, Richmond

. CXCR2 chemokine receptor—A master regulator in cancer and physiology. Trends Mol Med, 2024; 30(1):37–55; doi: 10.1016/j.molmed.2023.09.003

Lazennec

, Richmond

. Chemokines and chemokine receptors: New insights into cancer-related inflammation. Trends Mol Med, 2010; 16(3):133–144; doi: 10.1016/j.molmed.2010.01.003

10.

Yang

, Geng

, Yang

, et al. Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy. Cancer Cell, 2024; 42(12):2064–2081.e2019; doi: 10.1016/j.ccell.2024.10.008

11.

Delobel

, Ginter

, Rubio

, et al. CXCR2 intrinsically drives the maturation and function of neutrophils in mice. Front Immunol, 2022; 13:1005551; doi: 10.3389/fimmu.2022.1005551

12.

Suzuki

, Tanaka

, Li

, et al. Development of a sensitive anti-mouse CCR5 monoclonal antibody for flow cytometry. Monoclon Antib Immunodiagn Immunother, 2024; 43(4):96–100; doi: 10.1089/mab.2024.0004

13.

Tanaka

, Suzuki

, Isoda

, et al. Development of a sensitive anti-human CCR9 monoclonal antibody (C(9)Mab-11) by N-terminal peptide immunization. Monoclon Antib Immunodiagn Immunother, 2022; 41(6):303–310; doi: 10.1089/mab.2022.0027

14.

Ishikawa

, Suzuki

, Tanaka

, et al. Establishment of a high-affinity anti-mouse CXCR5 monoclonal antibody for flow cytometry. MI, 2024; 2; doi: 10.36922/mi.5664

15.

Ikota

, Nobusawa

, Arai

, et al. Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies. Brain Tumor Pathol, 2015; 32(4):237–244; doi: 10.1007/s10014-015-0222-8

16.

Kitamura

, Suzuki

, Kaneko

, et al. Cx(6)Mab-1: A novel anti-mouse CXCR6 monoclonal antibody established by N-terminal peptide immunization. Monoclon Antib Immunodiagn Immunother, 2022; 41(3):133–141; doi: 10.1089/mab.2022.0010

17.

Ludwig

, Ehlert

, Flad

, et al. Identification of distinct surface-expressed and intracellular CXC-chemokine receptor 2 glycoforms in neutrophils: N-glycosylation is essential for maintenance of receptor surface expression. J Immunol, 2000; 165(2):1044–1052; doi: 10.4049/jimmunol.165.2.1044

18.

Maas

, Soukup

, Fournier

, et al. The local microenvironment drives activation of neutrophils in human brain tumors. Cell, 2023; 186(21):4546–4566.e4527; doi: 10.1016/j.cell.2023.08.043

19.

Zhao

, Wu

, Liu

, et al. Disease-specific suppressive granulocytes participate in glioma progression. Cell Rep, 2024; 43(12):115014; doi: 10.1016/j.celrep.2024.115014

20.

Alshetaiwi

, Pervolarakis

, McIntyre

, et al. Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. Sci Immunol, 2020; 5(44):eaay6017; doi: 10.1126/sciimmunol.aay6017

21.

Highfill

, Cui

, Giles

, et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med, 2014; 6(237):237ra67; doi: 10.1126/scitranslmed.3007974

22.

Nishinakamura

, Shinya

, Irie

, et al. Coactivation of innate immune suppressive cells induces acquired resistance against combined TLR agonism and PD-1 blockade. Sci Transl Med, 2025; 17(785):eadk3160; doi: 10.1126/scitranslmed.adk3160

23.

Guo

, Sharp

, Gurel

, et al. Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance. Nature, 2023; 623(7989):1053–1061; doi: 10.1038/s41586-023-06696-z

24.

Prado

, Suetomi

, Shumate

, et al. Chemokine signaling specificity: Essential role for the N-terminal domain of chemokine receptors. Biochemistry, 2007; 46(31):8961–8968; doi: 10.1021/bi7004043

25.

Urvas

, Kellenberger

. Structural insights into molecular recognition and receptor activation in chemokine–Chemokine receptor complexes. J Med Chem, 2023; 66(11):7070–7085; doi: 10.1021/acs.jmedchem.3c00352

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.71 MB